Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › drug-induced liver injury

Drug-induced liver injury

Subtypes of Drug-induced liver injury

Hepatic adverse events 1

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for drug-induced liver injury

4 trials tracked for drug-induced liver injury: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 68 citations.

4Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 1 1 Other / NA 1
  1. Phase 4 Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics Completed · 68 cited
  2. Phase 4 Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days Completed
  3. Phase 1 Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions Completed
  4. N/A Sonoelastography: Ultrasound Method to Measure Liver Fibrosis Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review of phytochemicals in zebrafish models for metabolic dysfunction-associated steatotic liver disease and related conditions
Drug Pipeline Sys. Review
Narrative review of phytochemicals in zebrafish models for metabolic dysfunction-associated steatotic liver disease and related conditions Tiny fish help find new safe liver disease drugs
This narrative review examines preclinical data on phytochemicals using zebrafish models for metabolic dysfunction-associated steatotic live…
Tiny zebrafish are helping scientists test plant-based medicines for liver disease faster than ever before while checking safety and toxicit…
Frontiers Apr 28, 2026
In silico modeling shows acetaminophen overdose levels affect liver damage sensitivity and metabolic parameters
Drug Pipeline Cohort
In silico modeling shows acetaminophen overdose levels affect liver damage sensitivity and metabolic parameters New computer models predict who is most at risk from acetaminophen overdose
This in silico modeling study evaluated a representative patient cohort exposed to acetaminophen overdose at lower and higher levels.
This research helps us understand why some people suffer worse liver damage from acetaminophen overdose, paving the way for safer drug use.
Frontiers Apr 21, 2026
CAM products associated with ACLF in 39.6% of patients with liver injury in retrospective cohort
Gastroenterology Cohort
CAM products associated with ACLF in 39.6% of patients with liver injury in retrospective cohort CAM products linked to liver failure and heavy metal contamination in patients
A retrospective cohort study of 91 consecutive patients with CAM-related adverse events at a South Indian tertiary center found that 39.6% d…
Many complementary medicine products tested contained dangerous heavy metals like cadmium linked to severe liver failure and death in patien…
Frontiers Apr 9, 2026
In Silico Modeling Predicts Fezolinetant Hepatotoxicity Risk in MAFLD Population
Gastroenterology Phase II
In Silico Modeling Predicts Fezolinetant Hepatotoxicity Risk in MAFLD Population Could a menopause drug harm the liver? A computer model offers clues
Quantitative systems toxicology modeling simulated fezolinetant hepatotoxicity in virtual populations.
A computer model predicts a menopause drug might cause rare liver injury in people with fatty liver disease, but higher doses could be safer…
Apr 6, 2026
High-dose melatonin linked to hepatotoxicity in small PP-MS trial, prompting early halt
Neurology RCT
High-dose melatonin linked to hepatotoxicity in small PP-MS trial, prompting early halt High-dose melatonin trial halted after liver safety concerns in MS patients
A phase I/II RCT of 8 patients with PP-MS on stable ocrelizumab found that adjunctive high-dose oral melatonin (300 mg/day) was associated w…
A high-dose melatonin trial for multiple sclerosis stopped early after three of four patients developed mild liver injury, though the issue …
Apr 4, 2026